论文部分内容阅读
目的:探讨microRNA34a在非霍奇金淋巴瘤中的表达情况及其临床意义。方法:对40例非霍奇金淋巴瘤组织和20例淋巴结反应性增生组织行microRNA34a的实时定量检测,并结合患者的临床资料进行分析。结果:microRNA34a在非霍奇金淋巴瘤中呈显著低表达,尤其是在中高危及高危患者中其表达更低。多因素分析显示,microRNA34a的表达情况是患者治疗后能否缓解的一个独立预测因素。结论:microRNA34a在非霍奇金淋巴瘤中低表达,且其表达情况可作为一个预示患者对常规化疗方案是否有反应的指标。
Objective: To investigate the expression of microRNA34a in non-Hodgkin’s lymphoma and its clinical significance. Methods: Real-time quantitative detection of microRNA34a in 40 non-Hodgkin’s lymphoma tissues and 20 lymph node-responsive hyperplasia tissues was performed and analyzed according to the clinical data of the patients. Results: The expression of microRNA34a was significantly lower in non-Hodgkin’s lymphoma, especially in low-risk and high-risk patients. Multivariate analysis showed that the expression of microRNA34a was an independent predictor of remission in patients after treatment. Conclusions: microRNA34a is low expressed in non-Hodgkin’s lymphoma and its expression may be used as a predictor of whether patients respond to conventional chemotherapy regimens.